SCHEMBL6426870

SCHEMBL6426870

Cc1c([C@H](CC2CCCC2)C(=O)O)c2c(F)c(O)ccc2n1C(=O)c1cccc(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
HSD11B1 P28845 1/20 0.34
POLB P06746 1/20 0.34
GRN P28799 1/20 0.33
SORT1 Q99523 1/20 0.33
PTGER1 P34995 2/20 0.33
GPR142 Q7Z601 1/20 0.33
PTGS2 P35354 1/20 0.33
SLC6A9 P48067 1/20 0.33
SLC6A5 Q9Y345 1/20 0.33
AKR1C3 P42330 1/20 0.33
AKR1C2 P52895 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6426519 0.91 TDP1 (0.37) KDM4EALDH1A1MEN1KMT2AHSD11B1
SCHEMBL6423796 0.90 METAP2 (0.36) METAP2L3MBTL1KDM4EALDH1A1CNR1
SCHEMBL6424262 0.90 AKR1C3 (0.36) KDM4EALDH1A1MEN1KMT2AHSD11B1
SCHEMBL6428281 0.90 AKR1C3 (0.40) KDM4EMEN1KMT2APTGS2AKR1C3
SCHEMBL6428226 0.89 TSHR (0.34) ALDH1A1HSD11B1PTGS2AKR1C3AKR1C2
SCHEMBL6426850 0.89 USP30 (0.33) MEN1KMT2AHSD11B1PTGS2AKR1C3
SCHEMBL6424757 0.88 GPR142 (0.36) METAP2L3MBTL1KDM4EALDH1A1CNR1
SCHEMBL6464700 0.88 PTGS2 (0.33) PTGS2AKR1C3AKR1C2
SCHEMBL6425717 0.88 AKR1C3 (0.40) KDM4EMEN1KMT2APTGS2AKR1C3
SCHEMBL6428230 0.87 TSHR (0.34) ALDH1A1HSD11B1PTGS2AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors FAAH2, FAAH, PTGES2 METAP2 693/4885L3MBTL1 4595/4885KDM4E 2209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.